A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Summary

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

Timeline

Start

2025-08-07

Primary completion

2028-09-14

Completion

2030-12-31

Drugs

Indications